- Trial phase
- Approved
- Time to market
- Already approved and marketed since 2003. No further regulatory steps pending.
- Why 3/10
- Risperdal Consta is already FDA-approved (2003) and has no pending regulatory decision, pivotal readout, or other hard binary catalyst scheduled. For Alkermes, it is a legacy third-party licensing/manufacturing revenue stream facing generic erosion, not a company-defining asset. ImpactScore is 3 per the rubric for an approved, marketed drug with no imminent new regulatory decision.
Risperdal Consta is a mature, generic-eroding asset for Alkermes. Watch the quarterly manufacturing and royalty revenue line for continued erosion as Lupin's generic gains share. The real value drivers for ALKS are its proprietary portfolio (ARISTADA, LYBALVI, VIVITROL, LUMRYZ) and the orexin pipeline readouts expected over the next year. Risperdal Consta itself has no upcoming binary catalyst.
Price Chart
Executive Summary
Risperdal Consta (risperidone long-acting injection) is an FDA-approved atypical antipsychotic for schizophrenia (approved 2003) and bipolar I disorder (approved 2009). It uses Alkermes' proprietary Medisorb microsphere technology for sustained release over two weeks. The drug is commercialized by Janssen (Johnson & Johnson), not Alkermes directly. Alkermes receives a 2.5% royalty on net sales and manufacturing revenue from producing the drug at its Wilmington, Ohio facility. A generic version from Lupin was FDA-approved in September 2025 and launched in November 2025, putting pressure on brand sales and Alkermes' related revenue. For Alkermes, Risperdal Consta is a legacy third-party revenue stream that has been declining, while the company's strategic focus is on its proprietary product portfolio (ARISTADA, LYBALVI, VIVITROL, LUMRYZ) and its orexin pipeline. There are no upcoming binary catalysts for this drug.
How It Works
Risperdal Consta is a long-acting injectable form of risperidone, an atypical antipsychotic medication. It works by balancing levels of dopamine and serotonin in the brain, which helps regulate mood, thoughts, and behaviors. The drug is encapsulated in biodegradable microspheres using Alkermes' Medisorb technology, which slowly releases the medication over two weeks after a single intramuscular injection. This eliminates the need for daily pills and helps patients maintain consistent drug levels.
Trial Status
Risperdal Consta is a commercially marketed product. It was originally approved by the FDA in 2003 for schizophrenia and received a supplemental approval in 2009 for bipolar I disorder. No new clinical trials are being conducted by Alkermes for this drug, as it is a mature product facing generic competition.
The Two-Sided Case
Upcoming Catalysts
- No upcoming binary catalysts for Risperdal Consta specifically. The drug is already approved and faces generic erosion. For Alkermes overall, the key catalysts are quarterly earnings reports showing manufacturing/royalty revenue trends and the company's orexin pipeline readouts expected over the next year.
Source Filing
The SecBot filing or press-release report that triggered this drug report:
Alkermes plc. 8-K ALKS ·Originating report